Dr. Moore is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
711 E Lamar Blvd Ste 200
Arlington, TX 76011Phone+1 817-795-7546- Is this information wrong?
Education & Training
- University of Texas Medical Branch HospitalsFellowship, Dermatopathology, 1996 - 1997
- University of Texas Medical Branch HospitalsResidency, Dermatology, 1993 - 1996
- University of Texas Medical Branch HospitalsInternship, Internal Medicine, 1992 - 1993
- Baylor College of MedicineClass of 1992
Certifications & Licensure
- TX State Medical License 1993 - 2025
- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Super Doctor SuperDoctors.com
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2010 Aug 01
- Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 Mar 01
- Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsRoflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Janet DuBois, Seth B Forman, Melinda Gooderham, Lawrence Green, Scott T Guenth...> ;Journal of the American Academy of Dermatology. 2024 May 1
- Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.Gagne-Henley, A., Chavda, R., York, J., Sforzolini, B., Holcomb, K., Del Rosso, J., Dreno, B., Schleicher, S., Moore, A., Rafal, E., Johnson, S., Dhawan, S., Ablon, G.> ;Dermatology and Therapy. 2024 Feb 1
- Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.Stephen Schleicher, Angela Moore, Elyse Rafal, Angelique Gagne-Henley, Sandra Marchese Johnson, Sunil Dhawan, Rajeev Chavda, J P York, Baldo Sforzolini, Kate Holcomb, ...> ;Dermatology and Therapy. 2023 Dec 1
- Join now to see all
Press Mentions
- Narrow Spectrum Tetracycline for Moderate-to-Severe AcneOctober 11th, 2019
- Novel Oral Antibiotic Treatment Seysara™ (Sarecycline) Now AvailableJanuary 17th, 2019
- Almirall's Seysara Now AvailableJanuary 17th, 2019
Professional Memberships
- Fellow
Other Languages
- Spanish, Chinese (Mandarin)
Hospital Affiliations
- Texas Health Arlington Memorial HospitalArlington, Texas
- Baylor University Medical CenterDallas, Texas
- Methodist Mansfield Medical CenterMansfield, Texas
External Links
- Arlington Center for Dermatologyhttp://acderm.com/ACD-WP/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: